Genentech says drug improves vision after 1 year

	Tweet

Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections.

The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal.

Genentech has said that U.S. regulators would likely require its drug to show a difference - in favor of Lucentis - of 15 letters. Each line on a reading chart consists of five letters, so a 15-letter difference is equivalent to the difference in reading three lines of a reading chart.

RELATED STORIES:
Impotence Drugs Linked to Blindness, FDA Warns   Toronto researchers discover novel circulation in human eye, new glaucoma treatment target   Detached Retina   Treating Lazy Eyes with a Joystick   Automatic Eyeglasses Prescriptions? New Formula Connects Optical Quality with Visual Acuity   Team led by Scripps Scientists increases understanding of two types of blindness   Simple Eye Scan Opens Window to Multiple Sclerosis   From eye to brain   Space missions may damage eyes   Type of blindness reported in some taking Viagra   “Fluorescent” Cells Give Early Warning for Eye Disease   Implant appears effective for treating inflammatory disease within the eye

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]